⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTMX News
CytomX Therapeutics, Inc.
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
globenewswire.com
CTMX
Form 8-K
sec.gov
CTMX
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
globenewswire.com
CTMX
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
globenewswire.com
CTMX
CytomX Therapeutics to Present at Upcoming February Conferences
globenewswire.com
CTMX
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
globenewswire.com
CRDF
CTMX
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
businesswire.com
CTMX
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
globenewswire.com
CTMX
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
globenewswire.com
VERA
GILD
SANG
CTMX
CytomX Therapeutics to Present at Upcoming December Investor Conferences
globenewswire.com
CTMX